These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 14599864)

  • 21. High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-up.
    Shapiro F; Schneider J; Markman M; Reichman BS; Venkatraman E; Barakat R; Almadrones L; Spriggs D
    Gynecol Oncol; 1997 Oct; 67(1):39-45. PubMed ID: 9345354
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparison of primary intraperitoneal chemotherapy to consolidation intraperitoneal chemotherapy in optimally resected advanced ovarian cancer.
    Suidan RS; St Clair CM; Lee SJ; Barlin JN; Long Roche KC; Tanner EJ; Sonoda Y; Barakat RR; Zivanovic O; Chi DS
    Gynecol Oncol; 2014 Sep; 134(3):468-72. PubMed ID: 25042672
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
    Armstrong DK; Bundy B; Wenzel L; Huang HQ; Baergen R; Lele S; Copeland LJ; Walker JL; Burger RA;
    N Engl J Med; 2006 Jan; 354(1):34-43. PubMed ID: 16394300
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase II trial of intraperitoneal cisplatin and etoposide for primary treatment of ovarian epithelial cancer.
    Howell SB; Kirmani S; Lucas WE; Zimm S; Goel R; Kim S; Horton MC; McVey L; Morris J; Weiss RJ
    J Clin Oncol; 1990 Jan; 8(1):137-45. PubMed ID: 2295904
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-Term Survival Analysis of Intraperitoneal versus Intravenous Chemotherapy for Primary Ovarian Cancer and Comparison between Carboplatin- and Cisplatin-based Intraperitoneal Chemotherapy.
    Eoh KJ; Lee JY; Nam EJ; Kim S; Kim YT; Kim SW
    J Korean Med Sci; 2017 Dec; 32(12):2021-2028. PubMed ID: 29115086
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intraperitoneal cisplatin chemotherapy in ovarian carcinoma patients who are clinically in complete remission.
    Menczer J; Ben-Baruch G; Rizel S; Brenner H
    Gynecol Oncol; 1992 Aug; 46(2):222-5. PubMed ID: 1500025
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up.
    Morgan RJ; Braly P; Cecchi G; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Parker P; Stein A; Cho J; Smith E; Coluzzi P; Najera L; Johnson D; Womack E; Doroshow JH
    Gynecol Oncol; 1999 Dec; 75(3):419-26. PubMed ID: 10600300
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of survival after second-line intraperitoneal cisplatin-based chemotherapy for advanced ovarian cancer.
    Piver MS; Recio FO; Baker TR; Driscoll D
    Cancer; 1994 Mar; 73(6):1693-8. PubMed ID: 7512437
    [TBL] [Abstract][Full Text] [Related]  

  • 29. First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up.
    Fujiwara K; Sakuragi N; Suzuki S; Yoshida N; Maehata K; Nishiya M; Koshida T; Sawai H; Aotani E; Kohno I
    Gynecol Oncol; 2003 Sep; 90(3):637-43. PubMed ID: 13678738
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chemotherapy of advanced ovarian cancer with 4'-O-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose-intensity.
    Lévi F; Benavides M; Chevelle C; Le Saunier F; Bailleul F; Misset JL; Regensberg C; Vannetzel JM; Reinberg A; Mathé G
    J Clin Oncol; 1990 Apr; 8(4):705-14. PubMed ID: 2179481
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer.
    Berry E; Matthews KS; Singh DK; Buttin BM; Lurain JR; Alvarez RD; Schink J
    Gynecol Oncol; 2009 Apr; 113(1):63-7. PubMed ID: 19201457
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer.
    Conte PF; Bruzzone M; Chiara S; Sertoli MR; Daga MG; Rubagotti A; Conio A; Ruvolo M; Rosso R; Santi L
    J Clin Oncol; 1986 Jun; 4(6):965-71. PubMed ID: 3519886
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Experience with intraperitoneal cisplatin and etoposide and i.v. sodium thiosulphate protection in ovarian cancer patients with either pathologically complete response or minimal residual disease.
    van Rijswijk RE; Hoekman K; Burger CW; Verheijen RH; Vermorken JB
    Ann Oncol; 1997 Dec; 8(12):1235-41. PubMed ID: 9496389
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide, doxorubicin, and cisplatin.
    Wilke H; Preusser P; Fink U; Gunzer U; Meyer HJ; Meyer J; Siewert JR; Achterrath W; Lenaz L; Knipp H
    J Clin Oncol; 1989 Sep; 7(9):1318-26. PubMed ID: 2769330
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Feasibility and safety of a modified outpatient regimen with intravenous/intraperitoneal chemotherapy for optimally debulked stage III ovarian cancer.
    Bruixola G; Domingo S; Díaz R; Caballero J; Palomar L; De La Cueva H; Santaballa A
    Int J Gynecol Cancer; 2015 Feb; 25(2):214-21. PubMed ID: 25415075
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup phase II trial.
    Rothenberg ML; Liu PY; Braly PS; Wilczynski SP; Hannigan EV; Wadler S; Stuart G; Jiang C; Markman M; Alberts DS
    J Clin Oncol; 2003 Apr; 21(7):1313-9. PubMed ID: 12663720
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Feasibility of a modified outpatient regimen of intravenous/intraperitoneal chemotherapy in optimally debulked stage III ovarian cancer patients: a GEICO study.
    Oaknin A; Roda D; González-Martín A; Chiva L; García-Donas J; de Juan A; Redondo A; Martínez S; García Y; Catot S; Ponce J; Del Campo JM; Cervantes A; Poveda A
    Int J Gynecol Cancer; 2011 Aug; 21(6):1048-55. PubMed ID: 21738038
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Paclitaxel, cisplatin, and epirubicin first-line chemotherapy in stage III and IV ovarian carcinoma: long-term results of a phase II study.
    Papadimitriou CA; Moulopoulos LA; Vlahos G; Voulgaris Z; Kiosses E; Georgoulias N; Gika D; Diakomanolis E; Michalas S; Dimopoulos MA
    Cancer; 2000 Oct; 89(7):1547-54. PubMed ID: 11013370
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Survival with intraperitoneal cisplatin in advanced ovarian cancer after second-look laparotomy.
    de Gramont A; Demuynck B; Louvet C; Gonzalez-Canali G; Varette C; Pigné A; Marpeau L; Herbulot P; Lagadec B; Cady J
    Am J Clin Oncol; 1992 Feb; 15(1):7-11. PubMed ID: 1550083
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase I-II study with intraperitoneal cisplatin plus systemic etoposide in patients with minimal residual ovarian cancer.
    Willemse PH; Sleijfer DT; de Vries EG; Boonstra H; Bouma J; Mulder NH
    Eur J Cancer; 1992; 28(2-3):479-81. PubMed ID: 1591067
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.